More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel disease

被引：1
|
作者：
Kakiuchi, Toshihiko [1 ]
Yoshiura, Masato [1 ]
机构：
[1] Saga Univ, Fac Med, Dept Pediat, 5-1-1 Nabeshima, Saga 8498501, Japan
来源：
DIGESTIVE AND LIVER DISEASE | 2023年 / 55卷 / 02期
关键词：
ULCERATIVE-COLITIS; REMISSION;
D O I：
10.1016/j.dld.2022.11.004
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：298 / 299
页数：2
相关论文
共 50 条
  • [1] Ulcerative Colitis Therapy: Vedolizumab as a First-line Biologic Agent?
    Metzger, Leandra
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (03): : 274 - 276
  • [2] Trends in choice of first-line biologic therapy for patients with inflammatory bowel disease: An observational cohort study
    Fernando, S.
    Abu-Rgeef, R.
    Menon, S.
    So, K.
    Venugopal, K.
    Picardo, S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 143 - 144
  • [3] A Practical Review on When and How to Select First-Line Biologic Therapy in Patients with Inflammatory Bowel Disease
    Frasca, Joseph D.
    Cheifetz, Adam S.
    PRACTICAL GASTROENTEROLOGY, 2020, 44 (08) : 32 - 43
  • [4] Loss of response after first-line biologic therapy in patients with inflammatory bowel disease: practical approach and management
    Busacca, A.
    Scrivo, B.
    Giuffrida, E.
    Guida, L.
    Carrozza, L.
    Calvaruso, V.
    Cappello, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S299 - S299
  • [5] First-Line Therapies in Inflammatory Bowel Disease
    Girardin, Marc
    Manz, Michael
    Manser, Christine
    Biedermann, Luc
    Wanner, Roger
    Frei, Pascal
    Safroneeva, Ekaterina
    Mottet, Christian
    Rogler, Gerhard
    Schoepfer, Alain M.
    DIGESTION, 2012, 86 : 6 - 10
  • [6] Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
    Sard, M. Calafat
    Pascual, I.
    Nos, P.
    Barrio, J.
    Gutierrez, A.
    Martin-Arranz, M. D.
    Ricart, E.
    Gomollon, F.
    Ausin, M. Sierra
    Huguet, J. M.
    Guardiola, J.
    Vera, I.
    Varela, P.
    Iglesias, E.
    Garcia-Planella, E.
    de Castro, L.
    Sepulcre, M. F. Garcia
    Sicilia, B.
    Fernandez-Salazar, L.
    Calvet, X.
    Munoz, F.
    Garcia-Lopez, S.
    Bermejo, F.
    Ramos, L.
    Montiel, P. Martinez
    Lorente, R.
    Cabriada, J. L.
    Piqueras, M.
    Marin-Jimenez, I.
    Esteve, M.
    Mesonero, F.
    Sese, E.
    Gisbert, J. P.
    Marquez, L.
    Busquets, D.
    Pajares, R.
    Canete, F.
    Manosa, M.
    Domenech, E.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 766 - 767
  • [7] Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?
    Argollo, Marjorie C.
    Allocca, Mariangela
    Furfaro, Federica
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (01) : 25 - 31
  • [8] Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases
    Liefferinckx, Claire
    Verstockt, Bram
    Gils, Ann
    Tops, Sophie
    Van Moerkercke, Wouter
    Vermeire, Severine
    Franchimont, Denis
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (06) : 750 - 758
  • [9] Biologicals first-line in chronic inflammatory bowel disease? No
    Herrlinger, K.
    Stange, E. F.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (36) : 1789 - 1789
  • [10] Failure of Vedolizumab as First-Line Biologic Does Not Decrease Response Rates of Second-Line Therapy
    Ritter, Timothy E.
    Fourment, Chris
    Okoro, Tracy C.
    Hardin, Thomas C.
    Van Anglen, Lucinda J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S381 - S382
12345